Selecting one or more of the options below will update the content below.

Age Group
Type of Study
Study Format
Location
Target Population
  • Observational Study
    Online

    Nature-based Virtual Reality Intervention for Depression in Alzheimer’s Disease (VRN-AD)

    What is this Study about?

    This study looks at how an at-home nature-based virtual reality (VR) program may help people living with Alzheimer’s Disease manage behavioural and psychological symptoms of dementia (BPSD), such as depression. Caregivers and/or study partners will have the option of taking part in the study and providing feedback regarding the VR intervention. This project will explore how virtual reality can be used as a non-pharmacological approach to prolong aging in place for individuals with BPSD, as BPSD contributes to rates of institutionalization.

    Eligibility Criteria

    • Are 50 years or older
    • Have been diagnosed with mild to early-moderate Alzheimer's disease (including mixed dementia)
    • Are medically stable and able to take part safely
    • Experience mild to moderate depressive symptoms
    • Feel comfortable using basic technology, such as a tablet or headset
    • Have access to Wi-Fi and a smart device (such as a phone or tablet) for online sessions and study apps
    • Have someone available to be present during all study sessions

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated with Alzheimer's Disease Psychosis

    What is this Study about?

    ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated with Alzheimer's Disease Psychosis (ADP).

    The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo for the treatment of hallucinations and delusions associated with ADP as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.

    Eligibility Criteria

    Male or female participants aged 55 to 90 years of age
    Must have a study partner
    Presence of psychotic symptoms for at least 2 months before Screening.

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients With Cerebral Amyloid Angiopathy (CAA)

    What is this Study about?

    The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months.

    Eligibility Criteria

    Male or female participants aged 50 years of age
    Has a history of previous clinical intracerebral hemorrhage.
    Has probable CAA.

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies as Assessed by Biomarker Status and Cognition

    What is this Study about?

    This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.

    Eligibility Criteria

    Male or female participants aged 50 years of age to 90.
    Report of objective or subjective memory concerns (by the participant and/or their informant) within the last year with or without a previous clinical diagnosis of MCI or dementia due to AD.

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)

    What is this Study about?

    The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).

    Eligibility Criteria

    Male or female participants aged 50 years of age to 90.
    Must have a study partner
    Participant- and/or Informant-reported history of cognitive decline with gradual onset and progression over the last 1 year before screening

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

    What is this Study about?

    The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

    Eligibility Criteria

    Male or female participants aged 55 years of age to 90.
    Must have a study partner
    History of agitation due to AD.

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    A Randomized, Placebo-controlled, Parallel Group, 72-week Study to Evaluate the Efficacy and Safety of VHB937 in Participants With Early Alzheimer's Disease Followed by an Extension

    What is this Study about?

    The purpose of this study is to find out whether treatment with VHB937 is safe and beneficial in people with early Alzheimer's disease. The study will evaluate the safety of VHB937, as well as its effects on memory and other thinking abilities, on daily activities, and on changes in the brain. The study will also observe and measure how VHB937 is processed by the body and how the body responds to it.
    Official Title

    Eligibility Criteria

    Male or female participants aged 50 years of age to 85.
    Must have a study partner
    Diagnosis of Mild Cognitive Impairment (MCI) due to AD or mild AD

    Recruitment End Date

    Find Out More
  • Clinical Trial
    UHN - TO Western - Dr. Tartaglia

    A Phase 1, Randomized, Placebo-controlled Study With a Double Blind Period With Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients With Alzheimer

    What is this Study about?

    The purpose of this study is to:Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) and Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration

    Eligibility Criteria

    Male or female participants aged 40 to 80 years of age
    Has mild cognitive impairment (MCI) or dementia due to AD

    Recruitment End Date

    Find Out More
  • Observational Study
    In-Person

    Examining the effects of creatine and exercise training on cognition in older adults with MCI

    What is this Study about?

    Older adults are at greater risk for experiencing a reduction in cognitive and physical function. It is imperative that we identify health behaviors and non-pharmacological (i.e., non-medication) interventions to mitigate these declines. One promising lifestyle intervention to prevent or delay the onset of such declines is exercise, which has been found to improve cognitive function (mental abilities used to perform simple and complex tasks), physical function (muscle mass, bone density) and brain health (structure and function). There is also research demonstrating that creatine, a naturally occurring compound in the body known to decrease with age, can increase muscle mass and bone density in older adults when supplemented. However, it is unclear what effects creatine may have on cognition and brain health in older adults. Thus, our project will investigate the effects of creatine supplementation on cognition and brain health in older adults when combined with different types of exercise. Given the safety, accessibility and known reduction in creatine levels with age, examining how creatine supplementation may benefit older adults is well worth investigating.

    Eligibility Criteria

    To be eligible to participate in this study you must:

    • be 60 years of age or older

    • be living independently in the community

    • have normal or corrected-to-normal vision and hearing

    • read, write, and speak English fluently

    • have feelings of memory decline in the past 5 years

    • be able to exercise at a moderate pace for 60 minutes 3x/week receive clearance from a medical doctor (once deemed eligible) to participate in an exercise program

    You are ineligible to participate in this study if you:

    • cannot partake or commit to exercise training 3x/week for 26 weeks or have regularly engaged in exercise (more than once per week) over the past 3 months

    • cannot partake or commit to consuming a daily supplement for 26 weeks or consumed nutritional supplements containing creatine monohydrate over the past 3 months

    • have a known allergy to creatine monohydrate or dextrose (glucose, D-glucose)

    • have been diagnosed with a neurological disorder (e.g., Alzheimer’s disease, Parkinson’s disease)

    • have pre-existing kidney disease, heart disease, or liver abnormalities

    • have one or more uncontrolled chronic or psychiatric conditions (e.g., hypertension, diabetes, depression, anxiety)

    • are taking medication that may impact kidney function (e.g., non-steroidal anti-inflammatory drugs, such as ibuprofen and naproxen)

    • are ineligible or uncomfortable with blood sampling.

    Recruitment End Date

    Find Out More